Global Hepatitis Report 2026
WHO warns current rates of progress are insufficient to meet all 2030 viral hepatitis elimination targets, underscoring the urgent need to accelerate prevention, testing, and treatment efforts worldwide. More
The document provides practical, evidence-based guidance to support countries in planning, implementing and scaling up needle and syringe programmes for people who inject drugs as part of comprehensive harm reduction responses. More
In a commentary, published in The Lancet Gastroenterology & Hepatology, frontline voices reveal how recent global health funding cuts are already disrupting hepatitis B and C services worldwide. More
The C-Free study concludes that community-based HCV treatment of people who use drugs in Thailand, within harm reduction settings, is safe and effective. More
One in nine people in prisons globally have a history of injecting drug use and their risk of HIV, viral hepatitis and TB is up to 45 times higher than in the general population. More
Scaling up needle and syringe programmes is essential for achieving global infectious disease-elimination goals and improving health outcomes among people who inject drugs. More
The 2025 update summarises key developments in harm reduction services, funding and drug policy since the launch of the 9th edition of the report in November 2024. More